Main content area

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection

Davis, Carl W., Jackson, Katherine J.L., McElroy, Anita K., Halfmann, Peter, Huang, Jessica, Chennareddy, Chakravarthy, Piper, Ashley E., Leung, Yvonne, Albariño, César G., Crozier, Ian, Ellebedy, Ali H., Sidney, John, Sette, Alessandro, Yu, Tianwei, Nielsen, Sandra C.A., Goff, Arthur J., Spiropoulou, Christina F., Saphire, Erica Ollman, Cavet, Guy, Kawaoka, Yoshihiro, Mehta, Aneesh K., Glass, Pamela J., Boyd, Scott D., Ahmed, Rafi
Cell 2019 v.177 no.6 pp. 1566-1582.e17
B-lymphocytes, Ebolavirus, animal diseases, enzyme-linked immunosorbent assay, epitopes, glycoproteins, humans, immunity, immunoglobulin G, longitudinal studies, monoclonal antibodies, neutralization, neutralizing antibodies
Ebola virus (EBOV) remains a public health threat. We performed a longitudinal study of B cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection induced lasting EBOV-specific immunoglobulin G (IgG) antibodies, but their subclass composition changed over time, with IgG1 persisting, IgG3 rapidly declining, and IgG4 appearing late. Striking changes occurred in the immunoglobulin repertoire, with massive recruitment of naive B cells that subsequently underwent hypermutation. We characterized a large panel of EBOV glycoprotein-specific monoclonal antibodies (mAbs). Only a small subset of mAbs that bound glycoprotein by ELISA recognized cell-surface glycoprotein. However, this subset contained all neutralizing mAbs. Several mAbs protected against EBOV disease in animals, including one mAb that targeted an epitope under evolutionary selection during the 2014 outbreak. Convergent antibody evolution was seen across multiple donors, particularly among VH3-13 neutralizing antibodies specific for the GP1 core. Our study provides a benchmark for assessing EBOV vaccine-induced immunity.